Viridian Therapeutics, Inc. (VRDN) Deep Dive Video
Summary
Viridian is positioned to break Tepezza’s TED monopoly with a faster IV regimen now—and a potentially market-expanding at-home SC franchise next—creating asymmetric upside into 2026’s binary catalysts.